SHANGHAI, Aug. 15,
2024 /PRNewswire/ -- On August
16, 2024 (local time), Sanyou Biopharmaceuticals
(Shanghai) Co., Ltd. officially
announced the launch of the "Sanyou Innovative Intelligent Antibody
Design oneClick+ Platform."
Sanyou Bio's Innovative Intelligent Antibody Design oneClick+
Platform, independently designed by Sanyou Bio, integrates 90% of
the mainstream antibody structures currently available on the
market and reported in the literature. The platform will feature
four major systems upon launch, including: "IgG like antibody",
"Nanobody (VHH)", "Single-chain fragment variable antibody (ScFv)",
and "VHH+ScFv". The entire platform encompasses over 100 different
configurations, significantly enhancing the potential for antibody
design.
Users can design antibodies on the oneClick+ platform through
two ways. 1) After selecting the configuration diagram, the user
enters the complete antibody sequence (including variable and
constant region sequences). The "oneClick+" system can
automatically perform sequence alignment and generate antibody
physicochemical properties and potential mutation reports; 2) After
selecting the configuration diagram, the user enters the variable
region sequence only (the constant region sequence, such as
antibody subtypes and mutations, will be selected from the Sanyou
Bio database). After completing the antibody sequence editing,
"oneClick+" will generate the corresponding antibody report, which
includes basic physicochemical information of the conformation,
antibody configuration diagram, and complete sequence.
Sanyou's "oneClick+" platform greatly accelerates antibody
design efficiency and free users from the complexities of patent
searches and software integration. Through simple and convenient
operation, the desired antibody sequences or structural diagrams of
the target antibody can be exported by just a few clicks, catering
to various customer needs in antibody design.
Dr. Guojun Lang, CEO of Sanyou
Bio, stated: "With the rapid development of intelligent technology,
the intelligent construction of biologic drugs has become an
inevitable path for industry development. It has also become a
powerful engine for improving customer experience, simplifying
business processes, and optimizing operational efficiency. The
launch of the 'oneClick+' platform marks a significant step forward
for Sanyou Bio in the field of intelligent antibody design. The
convenience it offers will completely revolutionize the way users
approach antibody design. We believe that the launch of the
'oneClick+' platform will provide our customers with an
unprecedented experience and contribute to the intelligent
development of the biopharmaceutical industry. Let us look forward
to a brighter and better future for biologic drugs with the support
of intelligent technology!"
About Sanyou Biopharmaceuticals
Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech
biotechnology enterprise focusing on R&D and services of
innovative biologic drugs. Sanyou has built the 4C business
patterns that integrate "differentiated CRO, integrated CDO,
innovative CPO and characteristic CRS", to accomplish the mission
"to make the R&D easy for innovative biologics".
Sanyou has established an integrated innovative biologic drug
R&D laboratory with advanced facilities, and has a professional
team with the majority holding a Ph.D. or master degree. Sanyou has
built three industry-leading innovative technology platforms
featured by "super-trillion, integration, and intelligence", which
are comprised of more than 50 sub-platforms with the core
innovative super-trillion phage display platform, and supported by
platforms of material preparation, biologics discovery, molecule
optimization, in vitro and in vivo efficacy, production cell
line construction, upstream and downstream process development,
preclinical R&D, industrialization development, etc.
Sanyou's business network has expanded to all parts of the
world, including Asia, US and
Europe, and established branches
in Boston, Philadelphia, San
Diego and London. Sanyou
has established friendly business relationships with more than 1000
pharmaceutical companies, drug R&D institutions and diagnostics
companies worldwide. Sanyou received National-level certification
as a high-tech enterprise and a Specialized and Sophisticated
enterprise, and passed the ISO9001 quality assurance certification
and GB/T intellectual property management system certification.
View original
content:https://www.prnewswire.com/news-releases/sanyou-bios-innovative-intelligent-antibody-design-oneclick-platform-is-officially-launched-302223431.html
SOURCE Sanyou Bio